This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novartis Gets Approval for Remicade Biosimilar in Europe
by Zacks Equity Research
Novartis' (NVS) Sandoz wins approval for a biosimilar version of Remicade in Europe, which should further strengthen its biosimilars portfolio.
Pfizer's Tafamadis Gets Breakthrough Therapy Designation
by Zacks Equity Research
Pfizer's (PFE) rare disease candidate, tafamidis, gets Breakthrough Therapy designation in the United States for the treatment of transthyretin cardiomyopathy.
Glaxo and J&J's Two-Drug HIV Regimen Juluca Gets EU Approval
by Zacks Equity Research
Glaxo (GSK) and partner J&J (JNJ) gain marketing approval in the EU for Juluca, a two-drug HIV treatment.
Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study
by Zacks Equity Research
Pfizer (PFE) announces positive top-line results from a phase III study in pediatric epilepsy wherein Lyrica Oral Solution CV meets its primary endpoint.
Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug
by Zacks Equity Research
Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.
Dow 30 Stock Roundup: Walmart, Cisco, Home Depot Beat on Earnings
by Swarup Gupta
The Dow snapped a record streak of wins to traverse a turbulent week.
Roche Tecentriq Combo Achieves Longer Overall Survival Rate
by Zacks Equity Research
Roche's (RHHBY) immuno-oncology drug, Tecentriq, in combination with Avastin and chemotherapies leads to significantly longer overall survival rates in treatment-naive NSCLC patients.
Exelixis' Cabometyx Gets EU Nod for First-Line Kidney Cancer
by Zacks Equity Research
European Commission approves Exelixis' (EXEL) Cabometyx 20 mg, 40 mg and 60 mg for the first-line treatment of adults with intermediate- or poor-risk renal cell carcinoma in the European Union.
Pfizer Gets FDA Nod for Amgen, J&J's Anemia Drug Biosimilar
by Zacks Equity Research
Pfizer's (PFE) Retacrit, a biosimilar of Amgen's Epogen and J&J's Procrit gets FDA approval. The drug will be available for the treatment of anemia.
Merck KGaA (MKGAF) Q1 Earnings and Revenues Decline Y/Y
by Zacks Equity Research
Merck KGaA (MKGAF) reports dismal first-quarter results with earnings declining year over year. Revenues fall due to continued negative currency movement.
What's in the Cards for Merck KGaA (MKGAF) in Q1 Earnings?
by Zacks Equity Research
Merck's (MKGAF) Healthcare and Life Science segments to drive sales in Q1. However, operating expense is expected to be higher to support the launch of Bavencio and Mavenclad.
Will Trump's Surprise Drug Pricing Plan Boost Pharma Stocks?
by Ritujay Ghosh
Stocks of pharmaceutical companies get a boost as Trump's proposal will actually not directly hamper their profitability.
Merck vs. Pfizer: Which Stock Looks Better Post Q1 Earnings?
by Zacks Equity Research
Both Merck and Pfizer reported upbeat first-quarter results on May 1
Momenta (MNTA) Incurs Wider Y/Y Loss, Glatopa Sales Decline
by Zacks Equity Research
Momenta reported a wider year-over-year loss in the first quarter. Sales of Glatopa declined due to competition from Mylan.
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Pfizer, U.S. Bancorp, Tesla and Celgene
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Pfizer, U.S. Bancorp, Tesla and Celgene
Top Analyst Reports for Berkshire Hathaway, Pfizer & U.S. Bancorp
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway (BRK.B), Pfizer (PFE) and U.S. Bancorp (USB).
Drug/Biotech Q1 Earnings Lineup on May 8: JAZZ, ARNA & More
by Zacks Equity Research
The pharma/biotech industry has witnessed a mixed first-quarter earnings picture so far. Let's see what's in store for some of the smaller players.
Pharma Stock Roundup: Mixed Q1 for MRK, PFE, FDA Nod for Kymriah's 2nd Indication
by Zacks Equity Research
Earnings are in focus this week with Pfizer (PFE) and Merck (MRK) delivering mixed Q1 numbers. Novartis gains FDA approval for the second indication of its CAR-T therapy, Kymriah.
Q1 Earnings Drag Pharma ETFs Down
by Sweta Killa
Pharma ETFs saw terrible trading over the past month as mediocre results failed to boost confidence in the space, pushing many funds to 52-week lows.
Dow 30 Stock Roundup: AAPL, DWDP, CVX, MRK, MCD, PFE Beat on Earnings
by Swarup Gupta
The Dow endured a particularly tough week, ending with marginal gains for the first time only on Thursday.
What's in the Cards for Aerie (AERI) This Earnings Season?
by Zacks Equity Research
Investors are expected to focus on Rhopressa's launch and other pipeline updates when it reports results for the first-quarter (scheduled on May 8).
Company News for May 2, 2018
by Zacks Equity Research
Companies In The News are: PFE,MRK,THC,BP
ADP Job Data, Q1 Earnings In Focus
by Zacks Equity Research
ADP Job Data, Q1 Earnings In Focus
Jobs Week Shows New Wage Growth (and Lack Thereof)
by Mark Vickery
Paychex reported small-business jobs and wage growth for last month, and the results are definitely interesting.
Pfizer (PFE) Stock Falls on Q1 Sales Miss, Earnings Beat
by Zacks Equity Research
Pfizer (PFE) beats expectations for earnings but misses the same for revenues in the first quarter. It retains its previously issued guidance for 2018.